Vaxcyte
PCVX
66.96
+0.26
+0.39%
Vaxcyte
US · PCVX
#1630 by market cap
Listed 2020
66.96
+0.26
+0.39%
Live - 5344 symbols - heartbeat 232s ago
· 2026-10-08 06:54
Pre-market
66.19
-1.15%
After-hours
66.60
-0.54%
Overnight
66.59
-0.55%
- Market cap
- 9.96B
- P/E (TTM)i
- -8.78
- P/Bi
- 3.61
- EPSi
- -5.63
- Div yieldi
- 0.00%
- 52W posi
- 53%
Reader sentiment
Are you bullish or bearish on PCVX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.39M | 8.55M | 16.02M | 25.26M | 39.81M | 60.70M | 92.90M | 129.37M |
| Research & development | 30.15M | 45.61M | 73.56M | 78.41M | 169.45M | 332.34M | 476.64M | 794.31M |
| Operating profit | -35.53M | -53.92M | -87.10M | -102.09M | -209.26M | -393.04M | -569.55M | -923.68M |
| Pretax profit | -29.49M | -50.27M | -89.22M | -100.08M | -223.49M | -402.27M | -463.93M | -766.63M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -29.49M | -50.27M | -89.22M | -100.08M | -223.49M | -402.27M | -463.93M | -766.63M |
| Basic EPS | -1 | -2 | -3 | -2 | -3 | -4 | -4 | -6 |
| Diluted EPS | -1.15 | -1.96 | -3.02 | -1.93 | -3.44 | -4.14 | -3.80 | -5.63 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 32.66M | 32.04M | 32.45M | 32.22M | 33.07M | 34.93M |
| Research & development | 148.13M | 194.18M | 209.93M | 242.06M | 312.78M | 267.85M |
| Operating profit | -180.79M | -226.22M | -242.38M | -274.28M | -345.85M | -302.78M |
| Pretax profit | -140.72M | -166.57M | -212.83M | -246.51M | -320.62M | -284.30M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -140.72M | -166.57M | -212.83M | -246.51M | -320.62M | -284.30M |
| Basic EPS | -1 | -1 | -2 | -2 | -2 | -2 |
| Diluted EPS | -1.04 | -1.22 | -1.56 | -1.80 | -2.30 | -1.97 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 66.67M | 61.72M | 389.00M | 256.35M | 942.56M | 1.10B | 1.79B | 1.63B |
| Cash & ST investments | 66.09M | 58.98M | 386.20M | 245.97M | 931.38M | 1.08B | 1.75B | 1.56B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 70.80M | 65.70M | 392.83M | 324.34M | 1.01B | 1.41B | 3.51B | 3.00B |
| Total current liabilities | 6.71M | 11.05M | 46.86M | 28.72M | 40.53M | 145.34M | 140.18M | 205.75M |
| Short-term debt | 297.00K | 161.00K | -- | 5.28M | 5.91M | 7.11M | 5.89M | 6.12M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 128,530,000.00 | 172,071,000.00 | 46,983,000.00 | 40,319,000.00 | 52,565,000.00 | 167,449,000.00 | 205,499,000.00 | 317,207,000.00 |
| Total equity | -57.73M | -106.37M | 345.84M | 284.02M | 953.61M | 1.24B | 3.31B | 2.69B |
| Retained earnings | -59.07M | -109.35M | -198.56M | -298.64M | -522.13M | -924.39M | -1.39B | -2.15B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.72B | 1.72B | 1.77B | 1.63B | 1.81B | 1.55B |
| Cash & ST investments | 1.67B | 1.66B | 1.71B | 1.56B | 1.74B | 1.49B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 3.38B | 3.31B | 3.17B | 3.00B | 3.35B | 3.14B |
| Total current liabilities | 97.00M | 154.49M | 200.05M | 205.75M | 242.08M | 271.28M |
| Short-term debt | 6.13M | 6.30M | 5.77M | 6.12M | 6.09M | 6.51M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 178,077,000.00 | 234,029,000.00 | 278,718,000.00 | 317,207,000.00 | 352,294,000.00 | 380,212,000.00 |
| Total equity | 3.20B | 3.07B | 2.89B | 2.69B | 3.00B | 2.76B |
| Retained earnings | -1.53B | -1.70B | -1.91B | -2.15B | -2.48B | -2.76B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -30.47M | -47.15M | -46.63M | -121.39M | -170.60M | -296.79M | -452.63M | -655.58M |
| Depreciation & amortization | 1.04M | 1.23M | 1.41M | 3.46M | 9.45M | 10.17M | 15.85M | 24.86M |
| Free cash flow | -32.24M | -48.34M | -47.78M | -127.95M | -176.44M | -364.67M | -571.79M | -712.55M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 264.01M | 13.90M | 856.48M | 636.04M | 2.44B | 0 |
| Ending cash balance | 66.09M | 58.98M | 386.20M | 69.86M | 835.53M | 398.55M | 389.20M | 175.43M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -166.27M | -121.17M | -143.31M | -224.83M | -280.63M | -232.47M |
| Depreciation & amortization | 4.87M | 4.99M | 5.20M | 9.80M | 5.85M | 5.93M |
| Free cash flow | -193.03M | -130.92M | -155.35M | -233.25M | -295.42M | -237.05M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 0 | 601.85M | 0 |
| Ending cash balance | 348.17M | 308.06M | 282.55M | 175.43M | 262.31M | 184.66M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -74.51 | -31.78 | -36.12 | -36.67 | -20.41 | -25.59 |
| ROA %i | -41.64 | -83.03 | -38.91 | -27.91 | -33.59 | -33.33 | -18.86 | -23.54 |
| ROIC %i | -- | -- | -74.71 | -30.27 | -36.44 | -41.51 | -24.70 | -28.68 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -39.90 | -30.11 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 9.93 | 5.58 | 8.30 | 8.93 | 23.26 | 7.54 | 12.75 | 7.91 |
| Quick ratioi | 9.85 | 5.34 | 8.24 | 8.57 | 22.98 | 7.43 | 12.46 | 7.59 |
| Debt / assetsi | 0.65 | 0.25 | 0.00 | 5.17 | 1.78 | 2.08 | 2.03 | 3.91 |
| LT debt / equityi | -- | -- | -- | 4.05 | 1.26 | 1.78 | 1.97 | 4.15 |
| Interest coveragei | -392.13 | -1,255.85 | -12,744.29 | -14,295.71 | -111,741.50 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -19.66 | -21.65 | -20.83 | -25.59 | -30.55 | -36.51 |
| ROA %i | -18.64 | -20.31 | -19.53 | -23.54 | -28.14 | -33.03 |
| ROIC %i | -23.81 | -26.16 | -24.50 | -28.68 | -33.13 | -38.88 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 17.70 | 11.11 | 8.83 | 7.91 | 7.49 | 5.72 |
| Quick ratioi | 17.24 | 10.75 | 8.55 | 7.59 | 7.18 | 5.48 |
| Debt / assetsi | 2.58 | 2.60 | 2.66 | 3.91 | 3.47 | 3.68 |
| LT debt / equityi | 2.53 | 2.59 | 2.72 | 4.15 | 3.68 | 3.95 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 06:54:43 · For reference only, not investment advice and not tailored to your situation.